Biotechnology · Cambridge, MA · Founded 2021 · Privately Held (backing)
Developer of a biotechnological production platform intended to expand the reach of genome-editing-based therapies through the development of transformational biomaterials. Kano Therapeutics is based in Cambridge, MA and was founded in 2021. It was valued at $15 million at its seed round in Aug 2024, the last priced event on record. It has raised $7.4 million across 2 recorded rounds; the latest was a $5 million seed round in Aug 2024.
PMV mark · valuation
$15.0M
Oct 2026
Priced at
its seed round
Aug 2024
Total raised
$7.4M
Last round
Seed Round
Aug 2024
No prints on record
No secondary trades in Kano Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Kano Therapeutics with a free account
·The complete investor list: 12 names
·Watch Kano Therapeutics: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Kano Therapeutics stock.
